

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/715,636	11/18/2003	Martin Willard	10527-522001 / 03-257 4327	
26161 7590 09/28/2007 FISH & RICHARDSON PC			EXAMINER	
P.O. BOX 1022			STIGELL, THEODORE J	
MINNEAPOLIS, MN 55440-1022			ART UNIT	PAPER NUMBER
			3763	
			MAIL DATE	DELIVERY MODE
			09/28/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	H				
	Application No.	Applicant(s)			
-	10/715 <u>,</u> 636	WILLARD ET AL.			
Office Action Summary	Examiner	Art Unit			
	Theodore J. Stigell	3763			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from to cause the application to become ABANDONEL	l. ely filed the mailing date of this communication. 0 (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 25 Ju	ne 2007.				
2a) This action is <b>FINAL</b> . 2b) ☑ This	☐ This action is <b>FINAL</b> . 2b) ☐ This action is non-final.				
	) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.			
Disposition of Claims	·				
<ul> <li>4)  Claim(s) 1,2,4,7-18,21-25 and 41-49 is/are penders 4a) Of the above claim(s) is/are withdraw</li> <li>5) Claim(s) 1,2,4 and 7-17 is/are allowed.</li> <li>6)  Claim(s) 18 and 20-25 is/are rejected.</li> <li>7)  Claim(s) 41-49 is/are objected to.</li> <li>8)  Claim(s) are subject to restriction and/or</li> </ul>	vn from consideration.	·			
Application Papers					
9) The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the o		· ·			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 6/25/2007.  5. Patent and Trademark Office	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal Pa	te			

#### **DETAILED ACTION**

# Response to Amendment

Applicant's request for reconsideration of the finality of the rejection of the last Office action is persuasive and, therefore, the finality of that action is withdrawn.

## Claim Objections

Claims 41-49 are objected to under 37 CFR 1.75 as being a substantial duplicate of claims 1-2, 4, and 7-13. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k).

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 18 and 20-25 are rejected under 35 U.S.C. 102(b) as being anticipated by Ginsburg (5,989,238). Ginsberg discloses a method of cooling a target tissue region inside a body, the method comprising providing non-oxygenated fluid (saline solution) cooled below normal body temperature and oxygenated blood (all blood is at least partially oxygenated) at a normal body temperature (the fluid is injected through a catheter into a vessel which has blood of normal body temperature) to the tissue region in proportions to cool the tissue region and maintain, for an extended period of time

Art Unit: 3763

greater than two minutes, the temperature of the tissue region within a target range between 0-35 degrees Celsius which is 1-9 degrees below normal body temperature, wherein the blood is provided at least once every two minutes, wherein the fluid and blood are provided to the tissue region simultaneously, wherein a catheter provides blood to the tissue by partially occluding a vessel (any device in a vessel partially occludes the vessel just by being place there) in fluid communication with the tissue region to permit a restricted amount of blood to flow to the tissue region, wherein fluid is provided through the lumen of the catheter, wherein the tissue is maintained within the range of 28 to 36 C for at least two minutes, wherein the delivery can open a lesion in the vessel (drugs are disclosed being delivered), and wherein a control system controls the delivery.

# Allowable Subject Matter

Claims 1-2, 4, 7-17 are allowed.

### Response to Arguments

In regards to claim 18, the Applicant is relying on limitations that are not included in the claim. In regards to claim 41, the Examiner notes that the claim recites the same limitations as claim 1.

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Theodore J. Stigell whose telephone number is 571-272-8759. The examiner can normally be reached on M-F 8:30-5:00.

Application/Control Number: 10/715,636

Art Unit: 3763

Page 4

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nicholas Lucchesi can be reached on 571-272-4977. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Theodore J. Stigell

NICHOLAS D. LUCCHESI SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 3700